BTK Inhibitors: What Pharmacists Need To Know The PJ Pod podcast

Artwork

Science PJ Pod Pharmaceutical Journal

Contenuto fornito da The PJ Pod and Pharmaceutical Journal. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da The PJ Pod and Pharmaceutical Journal o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

The PJ Pod « »
BTK inhibitors: what pharmacists need to know

9M ago 31:54

Condividi

MP3•Pagina principale dell'episodio

Contenuto fornito da The PJ Pod and Pharmaceutical Journal. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da The PJ Pod and Pharmaceutical Journal o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them. In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.

… continue reading

43 episodi

#Science #PJ Pod #Pharmaceutical Journal

Artwork

BTK inhibitors: what pharmacists need to know

published 9M ago

Condividi

MP3•Pagina principale dell'episodio

Contenuto fornito da The PJ Pod and Pharmaceutical Journal. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da The PJ Pod and Pharmaceutical Journal o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them. In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.

… continue reading

43 episodi

#Science #PJ Pod #Pharmaceutical Journal

Tutti gli episodi

×

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

Ascolta più di 500 argomenti